Skip to main content
Clinical Trials/CTRI/2021/11/038268
CTRI/2021/11/038268
Recruiting
Phase 3

Metabolic resuscitation using early administration of ascorbic acid, thiamine and hydrocortisone in perioperative management of surgical patients with septic shock: A Randomized Controlled trial

AIIMS NEW DELHI0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: A419- Sepsis, unspecified organism
Sponsor
AIIMS NEW DELHI
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
AIIMS NEW DELHI

Eligibility Criteria

Inclusion Criteria

  • 1\. Perioperative septic shock: peritonitis due to hollow viscus perforation, ruptured solid organ abscess, pyoperitoneum, intestinal obstruction.
  • 2\. Controlled source of infection: Post\-intervention (surgical or non\-surgical) control of source of infection
  • 3\. 18 to 70 years, both gender
  • 4\. Ready to participate in the study

Exclusion Criteria

  • 1\. Age \< 18 years and \> 70 years
  • 2\. Refusal to consent and DNR orders (patient or patients family do not consent for the resuscitation and study)
  • 3\. Septic shock for \> 24 hours
  • 4\. Failure to administer intervention drugs within 6 hours of presentation of septic shock
  • 5\. Proven active COVID\-19 infection, HIV infection, known immunodeficiency diseases
  • 6\. Allergy to either of the intervention drugs (allergy to ascorbic acid or thiamine or hydrocortisone)
  • 7\. Uncontrollable source of infection e.g., Unresectable dead bowel,
  • 8\. Recurrent, unresectable or metastatic cancer
  • 9\. Patient on antifungal infection for systemic fungal infection
  • 10\. Imminent death or Inevitable deaths: metastatic cancer or haematological malignancy, more than four failed organs at entry (or multiorgan dysfunction syndrome), APACHE II score \> 30 at presentation, granulocytopenia leucocyte count \< 500cells/ml and/or thrombocytopenia \< 30000 cells/ml)

Outcomes

Primary Outcomes

Not specified

Similar Trials